drugset / Trial / NCT00785629
A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
Completed
148 enrolled
Denver Nephrologists, P.C.
DaVita, Inc. · collabFresenius Medical Care North America · collabGenzyme, a Sanofi Company · collabNovartis Pharmaceuticals · collabShire · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-07
- Completion
- 2011-07
Publications
- Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
- Dougher CE, Rifkin DE, Anderson CA, Smits G, Persky MS, Block GA, Ix JH. Spot urine sodium measurements do not accurately estimate dietary sodium intake in chronic kidney disease. Am J Clin Nutr. 2016 Aug;104(2):298-305. doi: 10.3945/ajcn.115.127423. Epub 2016 Jun 29.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcium carbonate | Other / unclassified | 667 mg | — |
| Comparator | Lanthanum Carbonate | Other / unclassified | 500 mg | — |
| Comparator | sevelamer | Other / unclassified | 800 mg | — |